Russia’s COVID-19 Vaccine Sputnik V Arrives In India; Govt Pins Hope On Five Coronavirus Vaccines Under Trial In India
Russia’s Sputnik V vaccine has reached India. The vaccine trials will begin at Dr Reddy’s Laboratories.
The Sputnik V vaccine made by Russia has finally arrived in India. The trial of these vaccines will soon kick off at Dr Reddy’s Laboratories to check the effectiveness of the COVID-19 vaccine. Here’s everything you need to know about the vaccine and its trials.
Sputnik V vaccine arrives in India
Russia’s coronavirus vaccine, the Sputnik V made it to Delhi earlier this week and has been sent to Dr Reddy’s Laboratories for testing. Dr Reddy’s laboratories got the nod to conduct an adaptive phase 2/3 human clinical trial for the vaccine in the country. In the video above, the containers with Sputnik V and Dr Reddy’s laboratories logos were being unloaded from the truck. Recently, Russia’s National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment fund announced that the Sputnik V vaccine has proved to be efficient up to 92%.
Earlier, on September 4, The Lancet, a world leading medical journal, published a research paper on the vaccine. The results of phase I and II clinical trial of the vaccine showed that there were no side effects of the vaccine and there was an effective immune response to the vaccine by the people. Meanwhile, Sputnik V’s first batch of vaccine is said to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College by next week. In Kanpur, the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted.
RB Kamal, the principal at the Ganesh Shankar Vidyarthi Medical College mentioned that there are more than 180 volunteers who have registered for the trial of the vaccine. One dosage will be given to these volunteers and they will be monitored for 7 months after which they will determine if they require another dosage of not. After observing the effect of the vaccine, the authorities will then take the decision of giving it to the other citizens.
Russia has received requests from more 50 countries for 1.2 billion doses of Sputnik V vaccine. Meanwhile, the central government in India is betting on 5 vaccine candidates that are currently under trial. Oxford-AstraZeneca candidate for which Pune-based Serum Institute is conducting phase 3 clinical trials, Bharat Biotech Covaxin which is also in phase 3 and the Sputnik V which is expected to start phase 2/3 trials next week. Other two candidates such as Cadila shot and Biological E are in phase 2 and phase 1/2 respectively.
Dr VK Paul, the member of Niti Aayog said that there is only one vaccine that has to be kept under 70-80 celsius temperature. It will be very difficult for many countries to scale up the distribution and even store them. In India, after the trials are complete, 30 crore people including frontline workers, senior citizens and healthcare workers will be first to be given the vaccine.
Read more trending stories on ZEE5!